- Home
- SDOT vs TXMD Comparison
SDOT vs TXMD Comparison
Compare SDOT & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SDOT | TXMD |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1M | 24.4M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | SDOT | TXMD |
|---|---|---|
| Price | $13.37 | $2.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 19.7K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 490.91 | 73.68 |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $7,929,137.00 | $1,761,000.00 |
| Revenue This Year | $12.76 | N/A |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | ★ N/A | $204.00 |
| Revenue Growth | ★ 60.08 | 35.25 |
| 52 Week Low | $0.14 | $0.99 |
| 52 Week High | $106.00 | $2.95 |
Technical Indicators
Market Signals| Indicator | SDOT | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 52.00 |
| Support Level | $12.11 | $1.93 |
| Resistance Level | $35.50 | $2.13 |
| Average True Range (ATR) | 3.70 | 0.06 |
| MACD | -1.01 | 0.00 |
| Stochastic Oscillator | 2.98 | 44.44 |
Price Performance
Historical ComparisonAbout SDOT Sadot Group Inc.
Sadot Group Inc consisted of one distinct operating unit engaged in the Agri-Foods industry. Its operating unit was intended to be a Agri-Foods company engaged in farming, commodity trading and shipping of food and feed (e.g., soybean meal, wheat and corn) via dry bulk cargo ships across the globe.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.